Morse is pleased to have supported the Myeloma Investment Fund (MIF) in its investment in Envisagenics, a biotechnology company pioneering the development of RNA splicing technology. The Myeloma Investment Fund, a subsidiary of the Multiple Myeloma Research Foundation (MMRF), views this investment in Envisagenics as a key opportunity to advance multiple myeloma research, and to pave the way for new treatments for the myeloma community.
Stephanie Oestreich, MIF’s Managing Director, stated, “We are excited to support Envisagenics in developing truly novel and potentially transformational therapies for multiple myeloma patients.”
The Myeloma Investment Fund is a venture philanthropy fund that invests in biotech companies developing innovative therapies and technologies to treat patients with multiple myeloma. Their goal is to provide enough financial and strategic support to advance therapies forward and improve the success rate for patients. As a philanthropic venture fund, 100% of the profits are reinvested back into research to continue supporting the development of effective treatments.
Morse corporate partner Jon Gworek, corporate associate Monica Sax, and intellectual property partner Stan Chalvire served as counsel to Myeloma Investment Fund on this transaction.
More information on the transaction can be found on the MIF site.
Morse focuses exclusively on the core legal services that businesses need to succeed, helping businesses of all sizes — from startups to Fortune 1000 companies — in the service areas of corporate, intellectual property, licensing, employment, taxation and litigation. Morse has a vibrant Venture Capital practice representing both the companies raising capital and institutional venture capital investors including the venture arms of foundations
Morse
CityPoint
480 Totten Pond Road, 4th Floor
Waltham, MA 02451
781-622-5930
morse.law
